Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

Abstract EN

Purpose.

To evaluate the cost-effectiveness of denosumab versus other osteoporotic treatments in older men with osteoporosis from a US payer perspective.

Methods.

A lifetime cohort Markov model previously developed for postmenopausal osteoporosis (PMO) was used.

Men in the model were 78 years old, with a BMD T-score of −2.12 and a vertebral fracture prevalence of 23%.

During each 6-month Markov cycle, patients could have experienced a hip, vertebral or nonhip, nonvertebral (NHNV) osteoporotic fracture, remained in a nonfracture state, remained in a postfracture state, or died.

Background fracture risks, mortality rates, persistence rates, health utilities, and medical and drug costs were derived from published sources.

Previous PMO studies were used for drug efficacy in reducing fracture risk.

Lifetime expected costs and quality-adjusted life-years (QALYs) were estimated for denosumab, generic alendronate, risedronate, ibandronate, teriparatide, and zoledronate.

Results.

Denosumab had an incremental cost-effectiveness ratio (ICER) of $16,888 compared to generic alendronate and dominated all other treatments.

Results were most sensitive to changes in costs of denosumab and the relative risk of hip fracture.

Conclusion.

Despite a higher annual treatment cost compared to other medications, denosumab is cost-effective compared to other osteoporotic treatments in older osteoporotic US men.